PubMed HealthSearch

Biomedical subjects

Ali Talyshinskii

Publications and source records attributed to Ali Talyshinskii.

2 recordsLinked to original sources

Advances in fragment removal devices in ureteroscopy: up-to-date review.

PURPOSE OF REVIEW: The development of laser lithotripsy for flexible ureteroscopy (fURS) has improved access and the ability to fragment renal stones. A common challenge for endourologists is managing the residual fragments (RF) of these stones. These RFs are associated with higher complication rates and the need for reinterventions and could serve as a focus for future stone formation. We aim to summarize recent technological advancements that increase the likelihood of removing more RFs and ultimately achieving stone-free status (SFS). RECENT FINDINGS: New technologies expand upon existing devices or create novel techniques, improving efficiency and increasing the volume of RF that can be extracted. Improvements to stone-grabbing baskets enable more controlled passes, reducing damage and complications. The flexible and navigable suction ureteric access sheath (FANS) builds on the traditional ureteral access sheath (UAS) by offering greater manoeuvrability and RF extraction from difficult anatomical locations. The development of urothelial-safe hydrogels provides an effective way to group and remove fragments. Additionally, magnetic hydrogels show promise for extracting tiny particles from hidden renal structures, advancing toward an ideal SFS. The Spinner-Induced Synergistic Circulation and Spiral Flow device also shows potential for rapidly removing numerous fragments. SUMMARY: Novel technological advancements build upon existing technologies or develop new methods of maximizing RF extraction while maintaining the balance of suction, irrigation, intrarenal pressure, and temperature - the Quadrifecta of retrograde intrarenal surgery (RIRS).

Humans

RADA16 as a novel hemostatic and regenerative agent in urology: European Association of Urology endourology up-to-date overview.

PURPOSE OF REVIEW: Self-assembling peptide (SAP) hydrogels represent a novel class of synthetic biomaterials with growing relevance in surgery. Among them, the ion-complementary peptide RADA16 has gained attention as an athermal, transparent, and biocompatible hemostatic agent. While its use is increasingly reported in multiple surgical specialties, evidence specific to urology remains fragmented. This review aims to summarize the physicochemical properties, mechanisms of action, and current clinical evidence for RADA16-based hydrogels, with a particular focus on urological applications. RECENT FINDINGS: RADA16 rapidly self-assembles into a transparent, extracellular-matrix-like nanofibrillar hydrogel upon exposure to physiological fluids, providing effective local hemostasis without reliance on the coagulation cascade. Preclinical and clinical data from other surgical fields demonstrate rapid bleeding control, favorable safety, and potential regenerative effects. Emerging urological evidence suggests that RADA16 is effective in managing hemorrhagic cystitis, radiation-induced hematuria, and bleeding during prostate surgery, including robot-assisted radical prostatectomy and benign prostate surgery. Beyond hemostasis, RADA16 may support wound healing and promotion of re-epithelialization. However, the current evidence base is limited by small sample sizes, lack of comparative studies, heterogeneous methodologies, and short follow-up. SUMMARY: RADA16-based hydrogels represent a promising adjunctive hemostatic option in urology, offering technical advantages such as transparency, absence of thermal injury, minimal swelling, and applicability in confined or high-risk settings. Robust prospective, comparative, and cost-effectiveness studies are required to define its definitive role in routine urological practice.

Humans